• Something wrong with this record ?

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial

S. Vermeire, WJ. Sandborn, S. Danese, X. Hébuterne, BA. Salzberg, M. Klopocka, D. Tarabar, T. Vanasek, M. Greguš, PA. Hellstern, JS. Kim, MP. Sparrow, KJ. Gorelick, M. Hinz, A. Ahmad, V. Pradhan, M. Hassan-Zahraee, R. Clare, F. Cataldi, W. Reinisch,

. 2017 ; 390 (10090) : 135-144. [pub] 20170517

Language English Country Great Britain

Document type Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial

Persistent link   https://www.medvik.cz/link/bmc18010545
E-resources Online Full text

NLK ProQuest Central from 1992-01-04 to 3 months ago
Nursing & Allied Health Database (ProQuest) from 1992-01-04 to 3 months ago
Health & Medicine (ProQuest) from 1992-01-04 to 3 months ago
Family Health Database (ProQuest) from 1992-01-04 to 3 months ago
Psychology Database (ProQuest) from 1992-01-04 to 3 months ago
Health Management Database (ProQuest) from 1992-01-04 to 3 months ago
Public Health Database (ProQuest) from 1992-01-04 to 3 months ago

Links

PubMed 28527704
DOI 10.1016/s0140-6736(17)30930-3
Knihovny.cz E-resources

BACKGROUND: PF-00547659 is a fully human monoclonal antibody that binds to human mucosal addressin cell adhesion molecule-1 (MAdCAM-1) to selectively reduce lymphocyte homing to the intestinal tract. We aimed to assess the efficacy and safety of PF-00547659 in patients with moderate to severe ulcerative colitis. METHODS: This phase 2, randomised, double-blind, placebo-controlled clinical trial recruited patients aged 18-65 years from 105 centres in 21 countries, with a history (≥3 months) of active ulcerative colitis extending more than 15 cm beyond the anal verge (with a total Mayo score ≥6 and a Mayo endoscopic subscore ≥2) who had failed or were intolerant to at least one conventional therapy. Patients were stratified by previous anti-TNFα treatment, and randomly assigned by a computer-generated randomisation schedule to receive a subcutaneous injection of 7·5 mg, 22·5 mg, 75 mg, or 225 mg PF-00547659 or placebo at baseline, then every 4 weeks. Patients, investigators, and sponsors were blinded to the treatment. The primary endpoint was the proportion of patients achieving remission (total Mayo score ≤2 with no individual subscore >1 and rectal bleeding subscore ≤1) at week 12. The efficacy analysis included all patients who received at least one dose of the randomised treatment; the safety analysis was done according to treatment received. All p values were one-sided and multiplicity-adjusted. This study is registered with ClinicalTrials.gov, number NCT01620255. FINDINGS: Between Nov 2, 2012, and Feb 4, 2016, we screened 587 patients; 357 were eligible and randomly assigned to receive placebo (n=73) or PF-00547659 at doses of 7·5 mg (n=71), 22·5 mg (n=72), 75 mg (n=71), or 225 mg (n=70). Remission rates at week 12 were significantly greater in three of four active-treatment groups than in the placebo group (2·7% [two of 73]): 7·5 mg (11·3% [eight of 71]), 22·5 mg (16·7% [12 of 72]), 75 mg (15·5% [11 of 71]), and 225 mg (5·7% [four of 70]). These rates corresponded to a stratum-adjusted (anti-TNFα-naive and anti-TNFα-experienced) risk difference versus placebo of 8·0% for 7·5 mg (90% CI 1·9 to 14, p=0·0425), 12·8% for 22·5 mg (5·6 to 19·9, p=0·0099), 11·8% for 75 mg (4·8 to 18·8, p=0·0119), and 2·6% for 225 mg (-1·2 to 6·4, p=0·1803). Four of 73 (5·5%) patients had a serious adverse event in the placebo group, ten of 71 (14·1%) in the 7·5 mg group, one of 70 (1·4%) in the 22·5 mg group, three of 73 (4·1%) in the 75 mg group, and three of 70 (4·3%) in the 225 mg group. No safety signal was observed for the study drug. INTERPRETATION: PF-00547659 was safe and well tolerated in this patient population, and better than placebo for induction of remission in patients with moderate to severe ulcerative colitis. The greatest clinical effects were observed with the 22·5 mg and 75 mg doses. FUNDING: Pfizer.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18010545
003      
CZ-PrNML
005      
20180418101358.0
007      
ta
008      
180404s2017 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S0140-6736(17)30930-3 $2 doi
035    __
$a (PubMed)28527704
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Vermeire, Séverine $u Leuven University Hospital and University of Leuven, Leuven, Belgium. Electronic address: severine.vermeire@uzleuven.be.
245    10
$a Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial / $c S. Vermeire, WJ. Sandborn, S. Danese, X. Hébuterne, BA. Salzberg, M. Klopocka, D. Tarabar, T. Vanasek, M. Greguš, PA. Hellstern, JS. Kim, MP. Sparrow, KJ. Gorelick, M. Hinz, A. Ahmad, V. Pradhan, M. Hassan-Zahraee, R. Clare, F. Cataldi, W. Reinisch,
520    9_
$a BACKGROUND: PF-00547659 is a fully human monoclonal antibody that binds to human mucosal addressin cell adhesion molecule-1 (MAdCAM-1) to selectively reduce lymphocyte homing to the intestinal tract. We aimed to assess the efficacy and safety of PF-00547659 in patients with moderate to severe ulcerative colitis. METHODS: This phase 2, randomised, double-blind, placebo-controlled clinical trial recruited patients aged 18-65 years from 105 centres in 21 countries, with a history (≥3 months) of active ulcerative colitis extending more than 15 cm beyond the anal verge (with a total Mayo score ≥6 and a Mayo endoscopic subscore ≥2) who had failed or were intolerant to at least one conventional therapy. Patients were stratified by previous anti-TNFα treatment, and randomly assigned by a computer-generated randomisation schedule to receive a subcutaneous injection of 7·5 mg, 22·5 mg, 75 mg, or 225 mg PF-00547659 or placebo at baseline, then every 4 weeks. Patients, investigators, and sponsors were blinded to the treatment. The primary endpoint was the proportion of patients achieving remission (total Mayo score ≤2 with no individual subscore >1 and rectal bleeding subscore ≤1) at week 12. The efficacy analysis included all patients who received at least one dose of the randomised treatment; the safety analysis was done according to treatment received. All p values were one-sided and multiplicity-adjusted. This study is registered with ClinicalTrials.gov, number NCT01620255. FINDINGS: Between Nov 2, 2012, and Feb 4, 2016, we screened 587 patients; 357 were eligible and randomly assigned to receive placebo (n=73) or PF-00547659 at doses of 7·5 mg (n=71), 22·5 mg (n=72), 75 mg (n=71), or 225 mg (n=70). Remission rates at week 12 were significantly greater in three of four active-treatment groups than in the placebo group (2·7% [two of 73]): 7·5 mg (11·3% [eight of 71]), 22·5 mg (16·7% [12 of 72]), 75 mg (15·5% [11 of 71]), and 225 mg (5·7% [four of 70]). These rates corresponded to a stratum-adjusted (anti-TNFα-naive and anti-TNFα-experienced) risk difference versus placebo of 8·0% for 7·5 mg (90% CI 1·9 to 14, p=0·0425), 12·8% for 22·5 mg (5·6 to 19·9, p=0·0099), 11·8% for 75 mg (4·8 to 18·8, p=0·0119), and 2·6% for 225 mg (-1·2 to 6·4, p=0·1803). Four of 73 (5·5%) patients had a serious adverse event in the placebo group, ten of 71 (14·1%) in the 7·5 mg group, one of 70 (1·4%) in the 22·5 mg group, three of 73 (4·1%) in the 75 mg group, and three of 70 (4·3%) in the 225 mg group. No safety signal was observed for the study drug. INTERPRETATION: PF-00547659 was safe and well tolerated in this patient population, and better than placebo for induction of remission in patients with moderate to severe ulcerative colitis. The greatest clinical effects were observed with the 22·5 mg and 75 mg doses. FUNDING: Pfizer.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a humanizované monoklonální protilátky $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D061067
650    _2
$a ulcerózní kolitida $x farmakoterapie $x patologie $7 D003093
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a gastrointestinální látky $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D005765
650    _2
$a lidé $7 D006801
650    _2
$a injekce subkutánní $7 D007279
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a indukce remise $7 D012074
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a výsledek terapie $7 D016896
650    _2
$a TNF-alfa $x antagonisté a inhibitory $7 D014409
650    _2
$a mladý dospělý $7 D055815
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Sandborn, William J $u University of California San Diego, La Jolla, CA, USA.
700    1_
$a Danese, Silvio $u Humanitas University, Clinical and Research Center, Humanitas Research Hospital, Rozzano, Milan, Italy.
700    1_
$a Hébuterne, Xavier $u Centre Hospitalier Universitaire de Nice Sophia Antipolis, Nice, France.
700    1_
$a Salzberg, Bruce A $u Atlanta Gastroenterology Specialists PC, Atlanta, GA, USA.
700    1_
$a Klopocka, Maria $u Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland.
700    1_
$a Tarabar, Dino $u Military Medical Academy, Clinic for Gastroenterology and Hepatology, Belgrade, Serbia.
700    1_
$a Vanasek, Tomas $u Charles University Hospital, Hradec Kralove, Czech Republic.
700    1_
$a Greguš, Miloš $u Gastroenterology Center, Nitra, Slovakia.
700    1_
$a Hellstern, Paul A $u Nature Coast Clinical Research, Inverness, FL, USA.
700    1_
$a Kim, Joo Sung $u Seoul National University College of Medicine, Seoul, South Korea.
700    1_
$a Sparrow, Miles P $u Alfred Hospital, Melbourne, VIC, Australia.
700    1_
$a Gorelick, Kenneth J $u Pfizer, Cambridge, MA, USA.
700    1_
$a Hinz, Michelle $u Pfizer, Cambridge, MA, USA.
700    1_
$a Ahmad, Alaa $u Pfizer, Cambridge, MA, USA.
700    1_
$a Pradhan, Vivek $u Pfizer, Cambridge, MA, USA.
700    1_
$a Hassan-Zahraee, Mina $u Pfizer, Cambridge, MA, USA.
700    1_
$a Clare, Robert $u Pfizer, Cambridge, MA, USA.
700    1_
$a Cataldi, Fabio $u Pfizer, Cambridge, MA, USA.
700    1_
$a Reinisch, Walter $u Medical University of Vienna, Vienna, Austria; McMaster University, Hamilton, ON, Canada.
773    0_
$w MED00010161 $t Lancet (London, England) $x 1474-547X $g Roč. 390, č. 10090 (2017), s. 135-144
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28527704 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180418101458 $b ABA008
999    __
$a ok $b bmc $g 1288030 $s 1007357
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 390 $c 10090 $d 135-144 $e 20170517 $i 1474-547X $m Lancet $n Lancet $x MED00010161
LZP    __
$a Pubmed-20180404

Find record

Citation metrics

Archiving options